No products in the cart.
Rabbit Polyclonal Phospho-Flt-1 (Y1213) antibody (STJ91359)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-1:2000; ELISA 1:40000;
Recommended protocols: check protocols
Click or hover above images to see image description for Flt-1 (phospho Tyr1213) Polyclonal Antibody.
Check alternative names for the antibodyExpand
FLT1 antibody, FLT antibody, FRT antibody, VEGFR1 antibody,|EC 18.104.22.168 antibody|ETV6 NTRK3 fusion antibody|GP145 TrkC antibody|gp145(trkC) antibody|GP145-TrkC antibody|GP145TrkC antibody|Neurotrophic tyrosine kinase receptor type 3 antibody|Neurotrophin 3 receptor antibody|NT 3 growth factor receptor antibody|NT 3 growth factor receptor precursor antibody|NT 3 receptor antibody|NT-3 growth factor receptor antibody|Ntrk3 antibody|NTRK3_HUMAN antibody|OTTHUMP00000192915 antibody|TRK C antibody|Trk-C antibody|TRKC antibody|TrkC tyrosine kinase antibody|Tyrosine kinase receptor C antibody|Anti-VEGF Receptor 1 antibody [Y103] (ab32152)
SCBT cat No: sc-316|sc-271789|sc-9029|sc-31173|
Flt-1 (phospho Tyr1213) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-Flt-1 (Y1213) Polyclonal Antibody detects endogenous levels of Flt-1 protein only when phosphorylated at Y1213.
Synthesized phospho-peptide derived from Flt-1 (phospho Tyr1213) at AA range 1150-1230
|Recommended dilution|| |
WB 1:500-1:2000; ELISA 1:40000;
|Molecular weight|| |
Flt-1 (phospho Tyr1213) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Flt-1 (phospho Tyr1213) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Vascular endothelial growth factor receptor 1 antibody, VEGFR-1 antibody, Fms-like tyrosine kinase 1 antibody, FLT-1 antibody, Tyrosine-protein kinase FRT antibody, Tyrosine-protein kinase receptor FLT antibody, FLT antibody, Vascular permeability factor receptor antibody
|Database links|| |
Human UniProt/Swiss-Prot:<a href="http://www.uniprot.org/uniprot/P17948">P17948</a>;Mouse UniPort/Swiss-Prot: <a href="http://www.uniprot.org/uniprot/P35969">P35969</a>;Rat UniProt/Swiss-Port: <a href="http://www.uniprot.org/uniprot/G3V633">G3V633</a>;Human Entrez Gene: <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=2321">2321</a>;Mouse Entrez Gene: <a href="http://www.ncbi.nlm.nih.gov/gene/14254">14254</a>;Rat Entrez Gene: <a href="http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Rn&CID=10239">Rn.10239</a>
|Protein names|| |
Vascular endothelial growth factor receptor 1 , VEGFR-1 , Fms-like tyrosine kinase 1 , FLT-1 , Tyrosine-protein kinase FRT , Tyrosine-protein kinase receptor FLT , FLT , Vascular permeability factor receptor
|Protein function|| |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. / ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. / Present in an inactive conformation in the absence of bound ligand. Binding of VEGFA, VEGFB or PGF leads to dimerization and activation by autophosphorylation on tyrosine residues.
|Protein tissue specificity|| |
Detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC).
|Involvement in disease|| |
Note: Can contribute to cancer cell survival, proliferation, migration, and invasion, and tumor angiogenesis and metastasis. May contribute to cancer pathogenesis by promoting inflammatory responses and recruitment of tumor-infiltrating macrophages.; Note: Abnormally high expression of soluble isoforms (isoform 2, isoform 3 or isoform 4) may be a cause of preeclampsia.
|Protein sequence and domain|| |
The second and third Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFA binding. / Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. / Contains 7 Ig-like C2-type (immunoglobulin-like) domains. / Contains 1 protein kinase domain.
|Protein post-translational modifications|| |
N-glycosylated. / Ubiquitinated after VEGFA-mediated autophosphorylation, leading to proteolytic degradation. / Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-1169 is important for interaction with PLCG. Phosphorylation at Tyr-1213 is important for interaction with PIK3R1, PTPN11, GRB2, and PLCG. Phosphorylation at Tyr-1333 is important for endocytosis and for interaction with CBL, NCK1 and CRK. Is probably dephosphorylated by PTPRB.
|Protein cellular localization|| |
Cell membrane; Single-pass type I membrane protein / Endosome / Secreted / Secreted / Secreted / Cytoplasm / Cytoplasm / Cytoplasm
|Research area|| |
<a href="http://antibodyplus.com/research-areas/">All research areas</a>><a href="http://antibodyplus.com/Membrane-Receptors/">Membrane Receptors</a>><a href="http://antibodyplus.com/product-tag/Flt/">Flt</a><br><a href="http://antibodyplus.com/product-tag/Membrane-Receptors/"> (View all antibody categories related to Membrane Receptors)</a>
AntibodyPlus can customize Flt-1 (phospho Tyr1213) Antibody according to your requirement, including bulk product size,etc. Please contact <a href="mailto:email@example.com">firstname.lastname@example.org</a>. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: